BrainChild Bio

Recent Finacing

Equity

Recent Raise

Undisclosed

BrainChild Bio is a clinical-stage biotech developing next-generation CAR T-cell therapies for CNS tumors—prioritizing pediatric DIPG—using multiplex targeting, novel transgenes, control switches and intraparenchymal administration across multiple clinical trials.

Founded 2023

Washington, United States

11-50

Private

brainchildbio.com

Highlights

Focus Areas

Biotechnology

Therapeutics

Recent Investors

Financials

1

Funding round

1

Investor

Team

Upgrade to view the team

See the team members at BrainChild Bio.